Developer docs
API playgroundTry for free, no card

Search company profiles

Neurelis

Full company profile

uuid0000bxb

Namestring
Neurelis
Legal namestring
Neurelis, Inc.
Websiteurl
neurelis.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Neurelis is a San Diego-based, privately held specialty pharmaceutical company founded in 2007 that develops and commercializes non-invasive intranasal therapies for neurological conditions. Its flagship product, VALTOCO (diazepam nasal spray), is the first FDA-approved nasal spray for the acute treatment of seizure clusters in patients aged two years and older, having received FDA approval and Orphan Drug Exclusivity in 2020 and a pediatric label expansion to ages 2-5 in April 2025. VALTOCO achieved 94% coverage of US insured lives (285+ million) within its first year on the market, with over 50,000 cartons prescribed and 12,000+ pediatric patients treated post-expansion.

The company's underlying value rests on three proprietary drug delivery technology platforms — Intravail® (transmucosal absorption enhancement), ProTek® (protein stabilization reducing immunogenicity), and Hydrogel™ (thixotropic delivery vehicle) — acquired through the 2019 purchase of Aegis Therapeutics, LLC. Beyond the direct VALTOCO franchise, these platforms are licensed to third parties and have produced FDA-approved products including TOSYMRA (Tonix Pharmaceuticals/Dr. Reddy's, acute migraine), OPVEE (Indivior, opioid overdose reversal), and neffy (ARS Pharmaceuticals, severe allergic reactions). Neurelis is also advancing two Phase 1 pipeline assets: NRL-1004 (intranasal olanzapine for acute agitation in schizophrenia/bipolar) and NRL-1049 (a Rho kinase inhibitor for cerebral cavernous malformations licensed from BioAxone).

Neurelis generates revenue primarily through VALTOCO product sales distributed via specialty pharmacy and retail pharmacy channels, supplemented by myNEURELIS — a patient support program offering nurse educators, insurance navigation, and savings programs. International revenue is captured through licensing partnerships with Aculys Pharma (nine Asia-Pacific markets) and China Medical System (Greater China). The company reported 2025 net revenue of $295-300M (more than doubling 2024) with EBITDA margins exceeding 30%, supported by a $175M+ cash position and no bank debt. The business model combines direct US commercial sales with a technology royalty stream, an emerging ex-US licensing footprint, and a CNS-focused pipeline leveraging the Intravail platform.

Short descriptiontext

Neurelis is a San Diego-based specialty pharmaceutical company that develops and commercializes intranasal therapies for neurological conditions, led by VALTOCO (diazepam nasal spray) for acute seizure clusters in patients aged two and older, and supported by proprietary Intravail®, ProTek®, and Hydrogel™ drug delivery platforms licensed to multiple partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, epilepsy therapeutics, intranasal drug delivery, seizure rescue medication, neurology drug development
Industry3 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals — Neurology / Epilepsy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1VALTOCO Product Sales
TypeOne Time License
Description

Primary revenue stream from direct sales of VALTOCO (intranasal diazepam) for acute seizure clusters, distributed through specialty pharmacy channels

2Intravail® Technology Licensing Royalties
TypeLicensing Royalties
Description

Royalty income from licensing proprietary drug delivery technology to pharmaceutical partners for their products (TOSYMRA, OPVEE, neffy)

Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Pricing details1 tier
1Patient assistance and support program
ModelOtherBilling cadencePay-as-you-go
Notes

myNEURELIS program provides patient assistance and insurance coverage support; specific pricing not publicly disclosed

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1VALTOCO
Description

FDA-approved diazepam nasal spray for acute treatment of seizure clusters in patients 2 years and older

neurelis.com
+4 more records
Core offering1 text field

Neurelis develops and commercializes specialty neurology therapeutics, with its flagship product VALTOCO (diazepam nasal spray) approved by the FDA for the acute treatment of seizure clusters in patients aged 2 and older. The company also monetizes its proprietary non-invasive drug delivery technology platforms (Intravail®, ProTek®, Hydrogel™) through licensing partnerships with pharmaceutical companies whose products (TOSYMRA, OPVEE, NEFFY) use these technologies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Achieved 94% US insured life coverage (285+ million lives) within first year of VALTOCO launch
+2 more records
Product overview1 text field

Neurelis is a neuroscience company with a diversified portfolio centered on its proprietary drug delivery technologies (Intravail, ProTek, Hydrogel) and a growing pipeline of CNS therapeutics. The commercial flagship is VALTOCO (diazepam nasal spray), FDA-approved for seizure clusters in patients 2+, while the proprietary pipeline includes NRL-1004 (Phase 1 acute agitation) and NRL-1049 (Phase 1 cerebral cavernous malformations). Technology licensing to partners has generated approved products including TOSYMRA, OPVEE, and NEFFY. The company also operates myNEURELIS, a patient support program for VALTOCO users.

Product and service4 records
1VALTOCO (diazepam nasal spray)
CategorySpecialty Pharmaceutical — Seizure Rescue Therapy
Description

FDA-approved diazepam nasal spray for the acute treatment of seizure clusters (episodes of frequent seizure activity) in patients 2 years of age and older. Uses proprietary Intravail® technology for non-invasive intranasal delivery.

2myNEURELIS patient support program
CategoryPatient Support Program
Description

Patient and care partner support program providing access to nurse educators, instructional information, assistance with pharmacy connections, and patient savings programs for VALTOCO users.

3Intravail® drug delivery technology (licensing program)
CategoryDrug Delivery Technology Platform — Licensing
Description

Proprietary non-invasive drug delivery technology enabling transmucosal delivery of proteins, peptides, and small molecule drugs, licensed to pharmaceutical partners for use in their commercial products.

4ProTek® protein stabilization technology (licensing program)
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1China Medical System
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Licensed VALTOCO for commercialization in China, Hong Kong, Taiwan, and Macau regions. Enables regional access for epilepsy patients with seizure clusters.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Licensed VALTOCO for commercialization in Australia, Brunei, Cambodia, Myanmar, New Zealand, Philippines, Singapore, Thailand, and Vietnam. Expands Asia-Pacific market access.

3Aegis Therapeutics, LLC
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Wholly-owned subsidiary providing proprietary drug delivery technology platforms (Intravail®, ProTek®, Hydrogel™) for non-invasive pharmaceutical delivery.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Commercializes TOSYMRA using Intravail® drug delivery technology for acute migraine treatment.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Commercializes OPVEE using Intravail® drug delivery technology for opioid overdose reversal.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensed neffy (epinephrine nasal spray) using Intravail® technology for severe allergic reaction treatment.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Licensed BA-1049 (now NRL-1049) for cerebral cavernous malformations treatment. Strategic partnership for rare disease pipeline development.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Associated with Tosymra commercialization, providing additional distribution and market access for migraine treatment product.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Develops intranasal drug delivery therapies for CNS and acute conditions (e.g., Trudhesa for migraine), directly paralleling Neurelis's intranasal VALTOCO approach and nasal-delivery platform strategy.

TypeDirect peer
Description

Commercializes OPVEE (intranasal nalmefene) for opioid overdose using Neurelis's Intravail platform; an adjacent player in the acute-rescue CNS category sharing Neurelis's nasal delivery platform and commercial channels.

TypeBroad incumbent
Description

Pure-play CNS specialty pharma with established epilepsy and neurology portfolios; competes for the same specialist prescribers that drive VALTOCO demand and represents a potential strategic acquirer.

TypeBroad incumbent
Description

Global CNS specialty pharma with leading epilepsy franchises (Briviact, Keppra, Vimpat) that compete head-to-head with VALTOCO for neurologist share-of-voice and formulary positioning.

TypeDirect peer
Description

Markets neffy, the first FDA-approved intranasal epinephrine spray built on Neurelis's licensed Intravail technology; competes with Neurelis's commercial team in CNS-adjacent acute-care rescue markets and validates the same platform.

TypeDirect peer
Description

Neurology-focused specialty pharma with epilepsy and CNS products; competes in the same physician channels and patient populations as Neurelis's VALTOCO and shares the specialty pharma commercial model targeting neurologists and epileptologists.

TypeRegional player
Description

US-focused neurology specialty pharma with epilepsy and seizure-cluster generics/biosimilar exposure (Vigadrone, Qudexy); competes in the same neurology patient pool and could enter diazepam nasal spray on a generic basis.

TypeDirect peer
Description

Specialty pharma developing oral and transmucosal drug delivery formulations for CNS indications, including a diazepam buccal film (Libervant) directly competing with Neurelis's VALTOCO in the seizure-cluster rescue market.

TypeDirect peer
Description

Licenses Neurelis's Intravail technology to commercialize TOSYMRA for acute migraine and develops CNS therapeutics; a platform partner whose commercial fate is partially tied to Neurelis's technology performance.

TypeBroad incumbent
Description

Diversified CNS/neurology specialty pharma (Xywav, Epidiolex, Sunosi) with the commercial infrastructure, payer relationships, and M&A track record that make it a natural strategic acquirer of a profitable CNS asset like Neurelis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neurelis

Specialty Pharmaceuticals — Neurology / Epilepsyneurelis.com

Neurelis is a San Diego-based specialty pharmaceutical company that develops and commercializes intranasal therapies for neurological conditions, led by VALTOCO (diazepam nasal spray) for acute seizure clusters in patients aged two and older, and supported by proprietary Intravail®, ProTek®, and Hydrogel™ drug delivery platforms licensed to multiple partners.

What Neurelis does

Neurelis is a San Diego-based, privately held specialty pharmaceutical company founded in 2007 that develops and commercializes non-invasive intranasal therapies for neurological conditions. Its flagship product, VALTOCO (diazepam nasal spray), is the first FDA-approved nasal spray for the acute treatment of seizure clusters in patients aged two years and older, having received FDA approval and Orphan Drug Exclusivity in 2020 and a pediatric label expansion to ages 2-5 in April 2025. VALTOCO achieved 94% coverage of US insured lives (285+ million) within its first year on the market, with over 50,000 cartons prescribed and 12,000+ pediatric patients treated post-expansion.

The company's underlying value rests on three proprietary drug delivery technology platforms — Intravail® (transmucosal absorption enhancement), ProTek® (protein stabilization reducing immunogenicity), and Hydrogel™ (thixotropic delivery vehicle) — acquired through the 2019 purchase of Aegis Therapeutics, LLC. Beyond the direct VALTOCO franchise, these platforms are licensed to third parties and have produced FDA-approved products including TOSYMRA (Tonix Pharmaceuticals/Dr. Reddy's, acute migraine), OPVEE (Indivior, opioid overdose reversal), and neffy (ARS Pharmaceuticals, severe allergic reactions). Neurelis is also advancing two Phase 1 pipeline assets: NRL-1004 (intranasal olanzapine for acute agitation in schizophrenia/bipolar) and NRL-1049 (a Rho kinase inhibitor for cerebral cavernous malformations licensed from BioAxone).

Neurelis generates revenue primarily through VALTOCO product sales distributed via specialty pharmacy and retail pharmacy channels, supplemented by myNEURELIS — a patient support program offering nurse educators, insurance navigation, and savings programs. International revenue is captured through licensing partnerships with Aculys Pharma (nine Asia-Pacific markets) and China Medical System (Greater China). The company reported 2025 net revenue of $295-300M (more than doubling 2024) with EBITDA margins exceeding 30%, supported by a $175M+ cash position and no bank debt. The business model combines direct US commercial sales with a technology royalty stream, an emerging ex-US licensing footprint, and a CNS-focused pipeline leveraging the Intravail platform.

Neurelis firmographics

Firmographics
Name
Neurelis
Legal name
Neurelis, Inc.
Website
https://neurelis.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
Neurelis is a San Diego-based specialty pharmaceutical company that develops and commercializes intranasal therapies for neurological conditions, led by VALTOCO (diazepam nasal spray) for acute seizure clusters in patients aged two and older, and supported by proprietary Intravail®, ProTek®, and Hydrogel™ drug delivery platforms licensed to multiple partners.
Ownership category
akta.pro rank

Neurelis industry classification

Industry
Product category
Specialty Pharmaceuticals — Neurology / Epilepsy
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Specialty pharmaceuticals
  • Epilepsy therapeutics
  • Intranasal drug delivery
  • Seizure rescue medication
  • Neurology drug development

Where Neurelis is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Neurelis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. VALTOCO Product Sales: Primary revenue stream from direct sales of VALTOCO (intranasal diazepam) for acute seizure clusters, distributed through specialty pharmacy channels
  2. Intravail® Technology Licensing Royalties: Royalty income from licensing proprietary drug delivery technology to pharmaceutical partners for their products (TOSYMRA, OPVEE, neffy)

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPatient assistance and support program

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Neurelis product offering

Product offering

Core offering

Neurelis develops and commercializes specialty neurology therapeutics, with its flagship product VALTOCO (diazepam nasal spray) approved by the FDA for the acute treatment of seizure clusters in patients aged 2 and older. The company also monetizes its proprietary non-invasive drug delivery technology platforms (Intravail®, ProTek®, Hydrogel™) through licensing partnerships with pharmaceutical companies whose products (TOSYMRA, OPVEE, NEFFY) use these technologies.

Product overview

Neurelis is a neuroscience company with a diversified portfolio centered on its proprietary drug delivery technologies (Intravail, ProTek, Hydrogel) and a growing pipeline of CNS therapeutics. The commercial flagship is VALTOCO (diazepam nasal spray), FDA-approved for seizure clusters in patients 2+, while the proprietary pipeline includes NRL-1004 (Phase 1 acute agitation) and NRL-1049 (Phase 1 cerebral cavernous malformations). Technology licensing to partners has generated approved products including TOSYMRA, OPVEE, and NEFFY. The company also operates myNEURELIS, a patient support program for VALTOCO users.

Differentiator

Problem solved

Functional benefit

Brands

  • VALTOCO: FDA-approved diazepam nasal spray for acute treatment of seizure clusters in patients 2 years and older
  • myNEURELIS
  • Intravail
  • ProTek
  • Hydrogel

Products and services

  • VALTOCO (diazepam nasal spray) FDA-approved diazepam nasal spray for the acute treatment of seizure clusters (episodes of frequent seizure activity) in patients 2 years of age and older. Uses proprietary Intravail® technology for non-invasive intranasal delivery.
  • myNEURELIS patient support program Patient and care partner support program providing access to nurse educators, instructional information, assistance with pharmacy connections, and patient savings programs for VALTOCO users.
  • Intravail® drug delivery technology (licensing program) Proprietary non-invasive drug delivery technology enabling transmucosal delivery of proteins, peptides, and small molecule drugs, licensed to pharmaceutical partners for use in their commercial products.
  • ProTek® protein stabilization technology (licensing program)

Quantifiable outcome

  • Achieved 94% US insured life coverage (285+ million lives) within first year of VALTOCO launch
  • +2 more outcomes

Companies that use Neurelis

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Neurelis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Neurelis partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • China Medical SystemcoreChannel Partner/ Reseller/ DistributorLicensed VALTOCO for commercialization in China, Hong Kong, Taiwan, and Macau regions. Enables regional access for epilepsy patients with seizure clusters.
  • Aculys PharmacoreChannel Partner/ Reseller/ DistributorLicensed VALTOCO for commercialization in Australia, Brunei, Cambodia, Myanmar, New Zealand, Philippines, Singapore, Thailand, and Vietnam. Expands Asia-Pacific market access.
  • Aegis Therapeutics, LLCcoreStrategic or Co-development PartnerWholly-owned subsidiary providing proprietary drug delivery technology platforms (Intravail®, ProTek®, Hydrogel™) for non-invasive pharmaceutical delivery.
  • Tonix PharmaceuticalsminorOEM/ Whitelabel/ Licensing PartnerCommercializes TOSYMRA using Intravail® drug delivery technology for acute migraine treatment.
  • IndiviorminorOEM/ Whitelabel/ Licensing PartnerCommercializes OPVEE using Intravail® drug delivery technology for opioid overdose reversal.
  • ARS PharmaceuticalsminorOEM/ Whitelabel/ Licensing PartnerLicensed neffy (epinephrine nasal spray) using Intravail® technology for severe allergic reaction treatment.
  • BioAxoneminorStrategic or Co-development PartnerLicensed BA-1049 (now NRL-1049) for cerebral cavernous malformations treatment. Strategic partnership for rare disease pipeline development.
  • Dr. Reddy's LaboratoriesminorChannel Partner/ Reseller/ DistributorAssociated with Tosymra commercialization, providing additional distribution and market access for migraine treatment product.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Neurelis competitors and assessment

Company assessment

Direct peers

  • Impel Pharmaceuticals: Develops intranasal drug delivery therapies for CNS and acute conditions (e.g., Trudhesa for migraine), directly paralleling Neurelis's intranasal VALTOCO approach and nasal-delivery platform strategy.
  • Indivior: Commercializes OPVEE (intranasal nalmefene) for opioid overdose using Neurelis's Intravail platform; an adjacent player in the acute-rescue CNS category sharing Neurelis's nasal delivery platform and commercial channels.
  • ARS Pharmaceuticals: Markets neffy, the first FDA-approved intranasal epinephrine spray built on Neurelis's licensed Intravail technology; competes with Neurelis's commercial team in CNS-adjacent acute-care rescue markets and validates the same platform.
  • Supernus Pharmaceuticals: Neurology-focused specialty pharma with epilepsy and CNS products; competes in the same physician channels and patient populations as Neurelis's VALTOCO and shares the specialty pharma commercial model targeting neurologists and epileptologists.
  • Aquestive Therapeutics: Specialty pharma developing oral and transmucosal drug delivery formulations for CNS indications, including a diazepam buccal film (Libervant) directly competing with Neurelis's VALTOCO in the seizure-cluster rescue market.
  • Tonix Pharmaceuticals: Licenses Neurelis's Intravail technology to commercialize TOSYMRA for acute migraine and develops CNS therapeutics; a platform partner whose commercial fate is partially tied to Neurelis's technology performance.

Broad incumbents

  • Lundbeck: Pure-play CNS specialty pharma with established epilepsy and neurology portfolios; competes for the same specialist prescribers that drive VALTOCO demand and represents a potential strategic acquirer.
  • UCB: Global CNS specialty pharma with leading epilepsy franchises (Briviact, Keppra, Vimpat) that compete head-to-head with VALTOCO for neurologist share-of-voice and formulary positioning.
  • Jazz Pharmaceuticals: Diversified CNS/neurology specialty pharma (Xywav, Epidiolex, Sunosi) with the commercial infrastructure, payer relationships, and M&A track record that make it a natural strategic acquirer of a profitable CNS asset like Neurelis.

Regional players

  • Upsher-Smith Laboratories: US-focused neurology specialty pharma with epilepsy and seizure-cluster generics/biosimilar exposure (Vigadrone, Qudexy); competes in the same neurology patient pool and could enter diazepam nasal spray on a generic basis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Neurelis social profiles

Digital presence

Neurelis compliance and trust

Trust signal

Compliance1 record

Neurelis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neurelis leadership team

Management profile

Number of profiles

Profiles12 records

Neurelis subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Neurelis funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neurelis M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurelis

What does Neurelis do?

Neurelis develops and commercializes specialty neurology therapeutics, with its flagship product VALTOCO (diazepam nasal spray) approved by the FDA for the acute treatment of seizure clusters in patients aged 2 and older. The company also monetizes its proprietary non-invasive drug delivery technology platforms (Intravail®, ProTek®, Hydrogel™) through licensing partnerships with pharmaceutical companies whose products (TOSYMRA, OPVEE, NEFFY) use these technologies.

Is Neurelis a public or private company?

Neurelis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neurelis founded?

Neurelis was founded in 2007. It employs 101 to 250 people.

Where is Neurelis based?

Neurelis is headquartered in San Diego, United States, in the North America region.

How does Neurelis make money?

Two revenue lines are on record. VALTOCO Product Sales are the primary driver. The others are intravail® Technology Licensing Royalties.

Who are Neurelis's main competitors?

Direct peers on record are Impel Pharmaceuticals, Indivior, ARS Pharmaceuticals, Supernus Pharmaceuticals, Aquestive Therapeutics and Tonix Pharmaceuticals. Broad incumbents are Lundbeck, UCB and Jazz Pharmaceuticals. Upsher-Smith Laboratories is listed as a regional player.

Does Neurelis have an API?

No public API is recorded for Neurelis.

What industry is Neurelis in?

Neurelis's product category is Specialty Pharmaceuticals — Neurology / Epilepsy. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooPodcast: Data beyond a study’s main objective provide strategic insightsA podcast episode discusses how post-hoc analyses of clinical trial data can reveal insights beyond a study's primary objective. It highlights using multiple data layers to uncover effects on specific population subsets. The episode features Craig Chambliss, CEO of Neurelis, at a 2026 conference.BioSpaceNEURELIS CEO CRAIG CHAMBLISS TO PRESENT KEYNOTE AT THE 14TH ANNUAL OUTSOURCING IN CLINICAL TRIALS SOUTHERN CALIFORNIA 2026 CONFERENCENeurelis CEO Craig Chambliss will give a keynote at the 14th Annual Outsourcing Clinical Trials Southern California 2026 conference in San Diego on September 15-16, 2026. His presentation will cover leveraging clinical data to generate publications and strategic insights, highlighting VALTOCO's impact on the epilepsy community.PR NewswireNEURELIS CEO CRAIG CHAMBLISS TO PRESENT KEYNOTE AT THE 14TH ANNUAL OUTSOURCING IN CLINICAL TRIALS SOUTHERN CALIFORNIA 2026 CONFERENCENeurelis CEO Craig Chambliss will keynote the 14th Annual Outsourcing Clinical Trials Southern California 2026 conference in San Diego on September 15-16, 2026. His talk, "Unlocking the Power of Clinical Data," will cover strategies to generate publications from VALTOCO clinical data and explore effects beyond initial study objectives.Clinical Trials ArenaClinical trial success increasingly dependent on strategic collaborations and tech applicationsArena International's Outsourcing in Clinical Trials Southern California conference returns for its 14th edition in September 2026 in San Diego. The event will feature sessions on AI, tech, and innovation, with keynotes from Craig Chambliss and Robert Goldman. The conference aims to discuss collaboration, budget planning, and patient participation in clinical trials.DrugPatentWatchOrphan Drug Exclusivity vs. Patent: Who Wins the Market WarThis article analyzes the interaction between Orphan Drug Exclusivity (ODE), a seven-year regulatory protection under the Orphan Drug Act, and patent protection in the U.S. pharmaceutical market, noting that patents outlast ODE in approximately 88% of cases but ODE becomes the primary barrier when composition-of-matter patents have expired or were never filed. The Catalyst Pharmaceuticals v. Becerra (2021) and Neurelis v. Brenner (2025) rulings created conflicting circuit interpretations on whether ODE covers an entire rare disease or only specific approved indications, with the D.C. Circuit appeal in Neurelis set to determine a potential national standard. The One Big Beautiful Bill Act signed in July 2025 expanded the IRA orphan drug exclusion to exempt any drug with one or more orphan designations from Medicare price negotiation as long as all approved indications remain rare diseases, representing a significant commercial benefit for the rare disease sector projected to exceed $400 billion annually by 2032.citybizNeurelis CEO Craig Chambliss Named EY Entrepreneur Of The Year 2026 Pacific Southwest WinnerNeurelis founder and CEO Craig Chambliss has been named an EY US Entrepreneur Of The Year 2026 Pacific Southwest Award winner, selected from nearly 1,000 participants across 17 regions. The recognition honors his leadership in advancing the neuroscience-focused biotechnology company from development-stage to commercial-stage, particularly through the successful development and commercialization of VALTOCO for seizure clusters. As a regional winner, Chambliss advances to consideration for the national awards in November and potentially the World Entrepreneur Of The Year award in 2027.SdbnNEURELIS CEO CRAIG CHAMBLISS NAMED EY US ENTREPRENEUR OF THE YEAR® 2026 PACIFIC SOUTHWEST AWARD WINNER – San Diego Biotechnology NetworkNeurelis CEO Craig Chambliss was named the EY US Entrepreneur of the Year 2026 Pacific Southwest Award winner, recognizing his entrepreneurial leadership at the pharmaceutical company behind VALTOCO (diazepam nasal spray). The award honors business leaders for ingenuity, courage, and entrepreneurial spirit. This is a recognition announcement from June 2026.PR NewswireNEURELIS CEO CRAIG CHAMBLISS NAMED EY US ENTREPRENEUR OF THE YEAR® 2026 PACIFIC SOUTHWEST AWARD WINNERCraig Chambliss, Founder and CEO of Neurelis, Inc., was named an EY US Entrepreneur Of The Year® 2026 Pacific Southwest Award Winner among nearly 1,000 program participants and 592 finalists across 17 regions. As a regional winner, Chambliss will now be considered by national judges for the Entrepreneur Of The Year 2026 National Awards to be presented in November, with the National Overall Award winner advancing to compete for the EY World Entrepreneur Of The Year™ Award in May 2027. Neurelis is a neuroscience company focused on epilepsy and neurologic disorders, with its FDA-approved product VALTOCO® (diazepam nasal spray) as its lead commercial therapy.PR NewswireNEURELIS HELPS SUPPORT NATIONAL NETWORK OF EPILEPSY AWARENESS AND SUPPORT AT FIRST EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT WALT DISNEY WORLDNeurelis, Inc. announced its participation in Epilepsy Awareness Day at Walt Disney World in Orlando, Florida, scheduled for April 25-26, 2026, marking the company's first east coast event for epilepsy awareness. The event, organized in partnership with Epilepsy Association of Florida, Epilepsy Alliance America, and Sophie's Journey, will feature Neurelis ambassadors sharing their experiences with epilepsy and the company's FDA-approved VALTOCO diazepam nasal spray treatment. Neurelis Founder and CEO Craig Chambliss stated the event aligns with the company's mission to connect medical education and support resources with patients and families living with epilepsy.BioSpaceNEURELIS TO PRESENT ANALYSES OF IMMEDIATE-USE SEIZURE TREATMENT AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETINGNeurelis will present two poster analyses at the AAN Annual Meeting on diazepam nasal spray for seizure clusters. The first shows timely termination of status epilepticus with few hospitalizations, and the second finds lower inpatient/outpatient visits and readmissions among patients with a prescription. The presentations occur April 19th in Chicago.